All formulations of hydroxyethyl starch are not the same
First published: 16 June 2007
No abstract is available for this article.
References
- 1
Auwerda JJA,
Leebeek FWG,
Wilson JHP, et al. Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch.
Transfusion
2006; 46: 1705-11.
- 2
Treib J,
Baron JF,
Grauer MT,
Strauss RG.
An international view of hydroxyethyl starches.
Intensive Care Med
1999; 25: 258-68.
- 3
Treib J,
Haas A,
Pindur G.
Coagulation disorders caused by hydroxyethyl starch.
Thromb Haemost
1997; 78: 974-83.
- 4
Treib J,
Haass A,
Pindur G, et al. HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics.
Thromb Haemost. 1995; 74: 1452-6.
- 5
Jonville-Béra A-P,
Autret-Leca E,
Gruel Y. Acquired type
I Von
Willebrand's disease associated with highly substituted hydroxyethyl starch.
N Engl J Med
2001; 345: 622-3.
- 6
Strauss RG,
Pennell BJ,
Stump DC.
A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch.
Transfusion
2002; 42: 27-36.
- 7
Hester JP,
McCredie KB,
Freireich EJ.
Response to chronic leukapheresis procedures and survival of chronic myelogenous leukemia patients.
Transfusion
1982; 22: 305-7.
- 8
Strauss RG,
Goeken JA,
Eckermann CM, et al. Effects of intensive granulocyte donation on donors and yields.
Transfusion
1986; 26: 441-5.
- 9
Strauss, Snyder EL,
Stuber J,
Fick Jr RB.
Ingestion of hydroxyethyl starch by human leukocytes.
Transfusion
1986; 26: 88-90.
